National Research Shares Cross 200-Day Average, Analysts Warn of Sell Signal

Shares of healthcare analytics firm National Research hit a key technical milestone, raising concerns among Wall Street analysts.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Shares of National Research Corporation (NASDAQ:NRC), a healthcare analytics and performance improvement company, have crossed above their 200-day moving average, a technical indicator that some analysts view as a potential sell signal. The stock last traded at $14.97, with a trading volume of over 260,000 shares. National Research has a market capitalization of $339.22 million and a P/E ratio of 29.94.

Why it matters

Crossing above the 200-day moving average is often seen as a bullish technical signal, but in National Research's case, at least one analyst has downgraded the stock to a 'sell' rating, citing the stock's valuation and performance. This highlights the ongoing debate among investors and analysts about how to interpret technical indicators, especially for companies in the healthcare analytics space.

The details

According to the report, National Research's share price has been trading above its 200-day moving average of $15.77. The stock reached as high as $15.92 on the day. However, one analyst has recently downgraded the stock from a 'hold' rating to a 'sell' rating, citing concerns about the company's valuation and performance. National Research has a current ratio of 0.55, a quick ratio of 0.55, and a debt-to-equity ratio of 5.36.

  • Shares of National Research crossed above the 200-day moving average on Monday, March 10, 2026.

The players

National Research Corporation

A healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company's cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools.

Weiss Ratings

A financial research and ratings agency that recently downgraded National Research's stock from a 'hold (c-)' rating to a 'sell (d+)' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The crossing of National Research's share price above its 200-day moving average has raised concerns among some analysts, who view this as a potential sell signal for the healthcare analytics firm. This highlights the ongoing debate around the interpretation of technical indicators, especially for companies in the rapidly evolving healthcare technology space.